/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

Mira Pharmaceuticals Inc

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$1.44 0(0%) MIRA at 04 Dec 2025 04:38 PM Drug Manufacturers - General
Lowest Today 1.41
Highest Today 1.46
Today’s Open 1.44
Prev. Close 1.44
52 Week High 2.45
52 Week Low 0.73
Day’s Range: Low 1.41 High 1.46
52-Week Range: Low 0.73 High 2.45
1 day return -
1 Week return -2.38
1 month return -8.3
3 month return +3.98
6 month return +2.13
1 year return +13.43
3 year return -
5 year return -
10 year return -

Institutional Holdings

Market Status

Strong Buy: 0

Buy: 0

Hold: 1

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 60.30 M

PB Ratio 8.2095

PE Ratio 0.0

Enterprise Value 58.45 M

Total Assets 2.92 M

Volume 192720

Company Financials

Annual Revenue FY23:0 0.0M, FY22:0 0.0M, FY21:0 0.0M

Annual Profit FY23:null 0.0M, FY22:null 0.0M, FY21:null 0.0M

Annual Net worth FY23:-7544444 -7.5M, FY22:-7058190 -7.1M, FY21:-2176536 -2.2M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:11161056 11.2M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:null 0.0M, Q2/2025:null 0.0M, Q1/2025:null 0.0M, Q3/2024:-2081619 -2.1M, Q2/2024:-1730722 -1.7M

Quarterly Net worth Q3/2025:-22694494 -22.7M, Q2/2025:-1537712 -1.5M, Q1/2025:-1783779 -1.8M, Q3/2024:-2043867 -2.0M, Q2/2024:-1691325 -1.7M

Fund house & investment objective

Company Information MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder. In addition, its oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is based in Miami, Florida.

Organisation Drug Manufacturers - General

Employees 0

Industry Drug Manufacturers - General

CEO Mr. Erez Aminov

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow